(Q33329874)

25 July 2017

title

Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer (English)

1 reference

25 July 2017

1 reference

1 reference

Scagliotti GV

1

1 reference

25 July 2017

Crinó L

2

1 reference

25 July 2017

Pozzi E

3

1 reference

25 July 2017

Corgna E

4

1 reference

25 July 2017

Selvaggi G

5

1 reference

25 July 2017

Novello S

6

1 reference

25 July 2017

Salsano G

7

1 reference

25 July 2017

Gentile A

8

1 reference

25 July 2017

Palladino M

9

1 reference

25 July 2017

Marracolo F

10

1 reference

25 July 2017

Tonato M

11

1 reference

25 July 2017

publication date

1 July 1999

1 reference

25 July 2017

1 reference

25 July 2017

volume

25

1 reference

25 July 2017

issue

1

1 reference

25 July 2017

page(s)

39-46

1 reference

New agents in non-small cell lung cancer

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900048-3

7 January 2021

Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900048-3

7 January 2021

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900048-3

7 January 2021

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900048-3

7 January 2021

Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900048-3

7 January 2021

Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900048-3

7 January 2021

Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900048-3

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900048-3

7 January 2021

Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900048-3

7 January 2021

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900048-3

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900048-3

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900048-3

7 January 2021

Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900048-3

7 January 2021

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900048-3

7 January 2021

Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900048-3

7 January 2021

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900048-3

7 January 2021

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2899%2900048-3

7 January 2021

10.1016/S0169-5002(99)00048-3

Identifiers

DOI

1 reference

25 July 2017

1 reference